Liraglutide
Also known as: GLP‑1 analog, liraglutide, NN2211, NN9535, Saxenda, Victoza
Source Liraglutide at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Liraglutide is a synthetic analogue of the hormone glucagon‑like peptide‑1 (GLP‑1) delivered by once‑daily subcutaneous injection. It is approved for the treatment of type 2 diabetes and, at a higher 3.0 mg dose, for chronic weight management in adults. Clinical trials have shown it can reduce body‑mass index and promote meaningful weight loss when combined with diet and exercise, and meta‑analyses suggest cardiovascular and renal benefits in people with type 2 diabetes.
Mechanism of Action
Liraglutide binds to the GLP‑1 receptor, a G‑protein‑coupled receptor expressed on pancreatic β‑cells, gastrointestinal neurons, and brain regions controlling appetite. Activation enhances glucose‑dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and increases satiety signals, leading to reduced caloric intake and improved glycaemic control. The prolonged half‑life of liraglutide results from fatty‑acid acylation that promotes albumin binding, allowing once‑daily dosing.
What the Research Shows
Randomised, placebo‑controlled trials in adults (SCALE Obesity, 56 weeks, n≈3,700) demonstrated that 3.0 mg liraglutide produced an average 8.4 kg weight loss versus 2.8 kg with placebo, with 63% achieving ≥5% loss. In children aged 6‑<12 years with obesity, a phase 3a trial (56 weeks, n=82) showed a mean BMI reduction of 5.8% versus a 1.6% increase on placebo, and 46% achieved ≥5% BMI loss. A head‑to‑head trial (STEP 8) found semaglutide superior to liraglutide, yet liraglutide still yielded a 6.4% weight reduction. A systematic review of cardiovascular outcome trials (including the LEADER trial of liraglutide) reported a 12% relative risk reduction in major adverse cardiovascular events and all‑cause mortality, plus renal benefits, without increased pancreatitis or pancreatic cancer. A 2025 review of discontinuation indicated weight regain after stopping GLP‑1RA therapy, highlighting challenges in long‑term maintenance.
Reported Benefits
Evidence from large adult trials shows liraglutide can produce clinically relevant weight loss (average 5–8 kg) and improve metabolic parameters when combined with lifestyle change. In children, the SCALE Kids trial demonstrated significant BMI reductions, suggesting potential utility in younger populations pending further study. Meta‑analysis of cardiovascular outcome trials indicates reduced risk of heart attack, stroke, cardiovascular death, and kidney disease in patients with type 2 diabetes, supporting added cardiometabolic benefit beyond weight loss.
Limitations of the Evidence
Long‑term weight‑maintenance data are limited; a 2025 systematic review noted weight regain after drug discontinuation. Pediatric data are confined to a single phase 3a trial with modest sample size, and liraglutide is not yet approved for children under 12. Head‑to‑head comparisons show semaglutide achieves greater weight loss, suggesting liraglutide may be less efficacious than newer agents. Most safety data derive from trials of 56–68 weeks, leaving uncertainty about very long‑term effects.
Safety Considerations
Across trials, gastrointestinal symptoms (nausea, diarrhea) were the most common adverse events, reported in 80‑84% of liraglutide recipients. Serious adverse events occurred in about 6% of participants, comparable to placebo. In the pediatric trial, 12% experienced serious events versus 8% with placebo. No increase in severe hypoglycaemia, pancreatitis, or pancreatic cancer was observed in pooled cardiovascular outcome analyses. Caution is advised in patients with a history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, per label warnings not detailed in the abstracts.
How It Is Administered
Liraglutide is supplied as a solution for subcutaneous injection. The approved dosing schedule for weight management involves daily injections, starting with a low dose and titrating up to 3.0 mg as tolerated. In clinical trials, dose escalation occurred over 4–16 weeks depending on the study. The formulation is a sterile aqueous solution administered using a prefilled pen or syringe.
Routes of Administration
Goals & Uses
- Non-alcoholic steatohepatitis (NASH)HepaticModerate
- Blood pressure reductionCardiovascularModerate
- Cardiovascular risk reductionCardiovascularHigh
- Appetite suppressionMetabolicHigh
- Weight loss / obesity managementMetabolicHigh
- Weight reductionMetabolicHigh
- Glycemic control in type 2 diabetesMetabolicHigh
- Glycaemic controlDiabetesHigh
Contraindications
- Personal or family history of medullary thyroid carcinomaOncologicHigh
- Severe renal impairment / end-stage renal diseaseRenalModerate
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
- Multiple endocrine neoplasia type 2OncologyHigh
- Medullary thyroid carcinomaOncologyHigh
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)Genetic/EndocrineHigh
- Known hypersensitivity to liraglutide or excipientsImmunologicModerate
- History of pancreatitisGastrointestinalModerate
- Hypersensitivity to liraglutide or excipientsImmunologicHigh
Adverse Effects
- PancreatitisGastrointestinalRareInflammation of the pancreas
- Injection site reactionsLocalCommon
- ConstipationGastrointestinalCommonReduced bowel frequency or difficulty passing stool
- Thyroid C-cell tumorsOncologicUnknown
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- VomitingGastrointestinalCommonForceful expulsion of stomach contents
- Acute pancreatitisGastrointestinalRare
- Hypoglycaemia (when combined with insulin or sulfonylureas)MetabolicUncommon
- DiarrhoeaGastrointestinalCommon
- DiarrheaGastrointestinalCommonLoose or frequent stools
Drug Interactions
- InsulinModerateMay increase risk of low blood sugar
- Insulin secretagogues (e.g., sulfonylureas)Moderate
- WarfarinLow
- Oral medications with narrow therapeutic indexLow
- Other GLP‑1 receptor agonistsHigh
- SulfonylureasModerateMay increase risk of low blood sugar
Population Constraints
- PregnancyReproductive SafetyRelative
- LactationReproductiveRelative
- Severe gastroparesisGastrointestinalRelative
- Severe hepatic impairmentOrgan ImpairmentRelative
- Severe renal impairment (eGFR <30 mL/min/1.73 m²)RenalRelative
- Pediatric patients under 12 yearsAgeAbsolute
- Children <18 yrAgeAbsolute
Regulatory Status
- European UnionApprovedApproved: type 2 diabetes mellitus, obesityMarketing authorisation granted 2010 (diabetes) and 2015 (obesity)
- United StatesApprovedApproved: type 2 diabetes mellitus, chronic weight managementVictoza (diabetes) approved 2010; Saxenda (obesity) approved 2014
- United KingdomApprovedApproved: type 2 diabetes mellitus, obesitySame as EU; NHS reimbursement for both indications
FDA approved Victoza (liraglutide 1.8 mg) for T2DM in 2010 and Saxenda (liraglutide 3.0 mg) for chronic weight management in 2014. EMA approvals followed. Carries a boxed warning regarding risk of thyroid C-cell tumors based on rodent studies.
Evidence & Sources
- Journal ArticleModerateFox CK, et al.2025-01-01T00:00:00.000000Z
- Journal ArticleModerateRubino DM, et al.2022-01-01T00:00:00.000000Z
- Journal ArticleHighKristensen SL, et al.2019-01-01T00:00:00.000000Z
- Journal ArticleModeratePi-Sunyer X, et al.2015-01-01T00:00:00.000000Z
- Journal ArticleHighBerg S, et al.2025-01-01T00:00:00.000000Z
- Journal ArticleModerateMarso SP, et al.2016-01-01T00:00:00.000000Z
Frequently Asked Questions
How does liraglutide differ from other GLP‑1 agonists?
Liraglutide is a once‑daily injectable with a fatty‑acid side chain that prolongs its action. Compared with weekly agents such as semaglutide, trial data show liraglutide produces weight loss, but the magnitude is generally lower; semaglutide achieved about 15.8% versus 6.4% weight reduction in a head‑to‑head study.
Is liraglutide approved for use in children?
No. While a phase 3a trial in children 6 to <12 years showed significant BMI reduction, liraglutide is not currently approved for pediatric obesity, and further studies are needed before regulatory approval.
What cardiovascular benefits does liraglutide provide?
A meta‑analysis of cardiovascular outcome trials, including the LEADER trial of liraglutide, found a 12% relative risk reduction in major adverse cardiovascular events, cardiovascular death, stroke, myocardial infarction, and all‑cause mortality, without added risk of severe hypoglycaemia or pancreatic disease.
Will weight loss be maintained after stopping liraglutide?
A 2025 systematic review of discontinuation studies suggests that weight tends to be regained after GLP‑1RA therapy is stopped, indicating that ongoing treatment may be required for sustained benefit.
What are the most common side effects?
The most frequently reported adverse events are gastrointestinal, chiefly nausea and diarrhea, occurring in 80‑84% of participants. Serious adverse events were reported in about 6% of users, similar to placebo rates.
What is Liraglutide?
Liraglutide is a synthetic analogue of the hormone glucagon‑like peptide‑1 (GLP‑1) delivered by once‑daily subcutaneous injection. It is approved for the treatment of type 2 diabetes and, at a higher 3.0 mg dose, for chronic weight management in adults. Clinical trials have shown it can reduce body‑mass index and promote meaningful weight loss when combined with diet and exercise, and meta‑analyses suggest cardiovascular and renal benefits in people with type 2 diabetes.
What is Liraglutide used for?
Liraglutide is educationally associated with: Non-alcoholic steatohepatitis (NASH), Blood pressure reduction, Cardiovascular risk reduction, Appetite suppression, Weight loss / obesity management, Weight reduction, Glycemic control in type 2 diabetes, Glycaemic control. Educational only — not medical advice.
How is Liraglutide administered?
Recorded routes of administration: Subcutaneous.
What are the potential side effects of Liraglutide?
Reported adverse effects include: Pancreatitis, Injection site reactions, Constipation, Thyroid C-cell tumors, Nausea, Vomiting, Acute pancreatitis, Hypoglycaemia (when combined with insulin or sulfonylureas), Diarrhoea, Diarrhea. This list is not exhaustive — consult a qualified clinician.
Who should avoid Liraglutide?
Recorded contraindications: Personal or family history of medullary thyroid carcinoma, Severe renal impairment / end-stage renal disease, Pregnancy, Multiple endocrine neoplasia type 2, Medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), Known hypersensitivity to liraglutide or excipients, History of pancreatitis, Hypersensitivity to liraglutide or excipients. Consult a qualified clinician before use.